Effects of Omega-3 fatty acids for psychotic disorders

Not Applicable

• Conditions: Schizophrenia, at-risk mental state (ARMS); schizophrenia

• Registration Number: JPRN-jRCTs041190054
• Lead Sponsor: Higuchi Yuko

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-07-22
• Study Completion: 2020-05-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

(1) Schizophrenia patients, fulfilled the criteria of DSM-5, (2) ARMS patients, fulfilled the criteria of CAARMS(the Comprehensive Assessment of At-Risk Mental State)

Exclusion Criteria

(1)Organic mental disorders, including epilepsy, having the history of head injury or alcohol dependence, (2)bleeding tendency or GI bleeding, (3)Mental retardation, (4)Infant(aged below 15 years old)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
(1)positive and negative syndrome scale(PANSS)<br>(2)diagnosis<br>(3)adverse reaction of Lotoriga

Secondary Outcome Measures

Name	Time	Method
(1)concentration of fatty acids in erythrocyte membranes<br>(2)Electroencephalogram(EEG):resting state, quantitative EEG, event related potentials(P300, mismatch negativity)<br>(3)Neurocognition<br>(4)Social cognition<br>(5)Neuroimaging:MRI